News & Updates

Sacituzumab govitecan improves survival in advanced breast cancer

18 Nov 2024

Treatment with sacituzumab govitecan (SG), a novel antibody-drug conjugate, provides survival benefits in women diagnosed with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) breast cancer, reports a study.

Sacituzumab govitecan improves survival in advanced breast cancer

18 Nov 2024

MVA-BN vax shows favourable safety, tolerability in adolescents in phase II study

18 Nov 2024 by

Interim data from a phase II trial demonstrate the safety and tolerability of the Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine in adolescents. MVA-BN is a live attenuated, non-replicating orthopoxvirus vaccine licensed in the US for smallpox and mpox prevention.

MVA-BN vax shows favourable safety, tolerability in adolescents in phase II study

18 Nov 2024

Abrocitinib provides early and sustained efficacy in atopic dermatitis

18 Nov 2024

Abrocitinib provides early relief of itch and skin pain as well as sustained efficacy for >2 years in patients with moderate-to-severe atopic dermatitis (AD), post-hoc analyses of JADE trials have shown. Notably, long-term efficacy was observed irrespective of prior exposure to systemic therapies.

Abrocitinib provides early and sustained efficacy in atopic dermatitis

18 Nov 2024

Day care attendance linked to lower T1D risk in children

18 Nov 2024

Children attending day care appear to be less likely than those who do not to have type 1 diabetes (T1D), according to the results of a meta-analysis.

Day care attendance linked to lower T1D risk in children

18 Nov 2024

Novel islatravir + lenacapavir combo maintains high viral suppression rates

18 Nov 2024 by

Once-weekly treatment with islatravir, an investigational nucleoside reverse transcriptase translocation inhibitor, and lenacapavir, a first-in-class HIV-1 capsid inhibitor, led to sustained high rates of viral suppression at week 48 among people with HIV, according to the secondary endpoint results of a phase II study presented at IDWeek 2024.

Novel islatravir + lenacapavir combo maintains high viral suppression rates

18 Nov 2024

Real-world Chinese data: Rimegepant effective, well tolerated in acute Tx of migraine

18 Nov 2024

Rimegepant as acute therapy is effective and well tolerated in real-world Chinese patients with migraine, including those with very-high-frequency migraine (VHFM) days, prior nonresponders (PNRs) to any acute or preventive migraine treatment, and those on concomitant eptinezumab as preventive treatment, a study in China has shown.

Real-world Chinese data: Rimegepant effective, well tolerated in acute Tx of migraine

18 Nov 2024

Original New Drug Application Approvals by US FDA (1-15 November 2024)

18 Nov 2024

New drug applications approved by US FDA as of 1-15 November 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1-15 November 2024)

18 Nov 2024

Early intratracheal budesonide does little to improve outcomes in preemies

17 Nov 2024

Early intratracheal budesonide in extremely preterm infants receiving surfactant for respiratory distress syndrome appears to be of little to no benefit in terms of survival free of bronchopulmonary dysplasia (BPD), according to a study.

Early intratracheal budesonide does little to improve outcomes in preemies

17 Nov 2024

Socioeconomic status tied to low use of adjuvant immunotherapy in stage III melanoma

17 Nov 2024

Patients with stage III melanoma show inconsistent use of adjuvant immunotherapy despite its survival benefits, according to a study.

Socioeconomic status tied to low use of adjuvant immunotherapy in stage III melanoma

17 Nov 2024

Depressive symptoms up risk of home hypertension

17 Nov 2024

Depressive symptoms are a risk factor for new-onset home hypertension, as reported in a study.

Depressive symptoms up risk of home hypertension

17 Nov 2024

News & Updates

Filter by Specialty:

Specialty:

Sacituzumab govitecan improves survival in advanced breast cancer

Sacituzumab govitecan improves survival in advanced breast cancer

MVA-BN vax shows favourable safety, tolerability in adolescents in phase II study

MVA-BN vax shows favourable safety, tolerability in adolescents in phase II study

Abrocitinib provides early and sustained efficacy in atopic dermatitis

Abrocitinib provides early and sustained efficacy in atopic dermatitis

Day care attendance linked to lower T1D risk in children

Day care attendance linked to lower T1D risk in children

Novel islatravir + lenacapavir combo maintains high viral suppression rates

Novel islatravir + lenacapavir combo maintains high viral suppression rates

Real-world Chinese data: Rimegepant effective, well tolerated in acute Tx of migraine

Real-world Chinese data: Rimegepant effective, well tolerated in acute Tx of migraine

Original New Drug Application Approvals by US FDA (1-15 November 2024)

Original New Drug Application Approvals by US FDA (1-15 November 2024)

Early intratracheal budesonide does little to improve outcomes in preemies

Early intratracheal budesonide does little to improve outcomes in preemies

Socioeconomic status tied to low use of adjuvant immunotherapy in stage III melanoma

Socioeconomic status tied to low use of adjuvant immunotherapy in stage III melanoma

Depressive symptoms up risk of home hypertension

Depressive symptoms up risk of home hypertension